Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nordea and Swedbank in connection with K2A’s establishment of its MTN programme
Mandate

Vinge advises Nordea and Swedbank in connection with K2A’s establishment of its MTN programme

May 21, 2021 Banking and Finance

Vinge has advised Nordea Bank Abp and Swedbank AB (publ) as lead arrangers and issuing agents in connection with the structuring, documenting and establishment of K2A Knaust & Andersson Fastigheter AB (publ) (”K2A”) unsecured medium term note programme (the “MTN Programme”). The MTN Programme is part of K2A’s debt financing and allows K2A to issue senior unsecured medium term notes in an aggregate amount of up to SEK 3,000,000,000 in SEK or EUR, with a minimum tenor of one year.

In contrast to customary MTN programmes, the MTN Programme was structured to be aligned with the terms and structure of high yield bonds issued on a standalone basis – making the MTN Programme one of the first of its kind in Sweden.

K2A has prepared a base prospectus which has been approved by, and registered with, the Swedish Financial Supervisory Authority.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda and Felix Möller.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024